BÜHLMANN IBDoc® Archives - Page 2 of 3 - Buhlmann Diagnostics Corp

Tag: BÜHLMANN IBDoc®

Connect with BUHLMANN at CDDW 2019!

Canadian Digestive Diseases Week (CDDW) 2019 BUHLMANN Diagnostics Corp Booth: #116 Mar 1 - 3, 2019 | Fairmont Banff Springs Hotel | Banff Alberta Learn More Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the ONLY in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh,  A,  Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625   DOI: doi.org/10.1093/ecco-jcc/jjy184  Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading

Can mHealth Apps replace clinic visits?

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. Highlight from this Article In this study, 233 separate apps were found on
Continue Reading

Introducing Patient Home Tests for Calprotectin in a Routine District General Hospital

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “In the six months that we have been working with the IBDoc, one patient was
Continue Reading

BUHLMANN LabSense News Summer 2018 Edition

In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to
Continue Reading

IBDoc – SwissMedtech Award Nominee

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test    About Swiss MEDTECH Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster.
Continue Reading

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading